HNSCC – Medxy AI

Liquid Biopsy Predicts Recurrence in HPV-Independent Head and Neck Cancer Months Before Imaging

By MedXY 03/23/2026

A prospective study demonstrates that tumor-informed ctDNA-based minimal residual disease (MRD) testing significantly predicts recurrence and survival in HPV-independent HNSCC, offering a median five-month lead time over clinical detection and standard imaging.

news Oncology Otorhinolaryngology

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

By MedXY 01/13/2026

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcinoma.

news Oncology Otorhinolaryngology

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

By MedXY 01/11/2026

The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma, with survival data actually favoring the control group.

Clinical Updates news Oncology Otorhinolaryngology

Precision Prognosis: Navigating Decision-Making in Head and Neck Cancer Through Individualized Counseling

By MedXY 01/06/2026

This review analyzes the impact of individualized prognostic counseling on decisional conflict and regret in patients with head and neck squamous cell carcinoma, highlighting the efficacy of online prognostic tools in fostering shared decision-making and patient engagement.

news Oncology Otorhinolaryngology Pathology & Lab Medicine

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

By MedXY 12/22/2025

A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate endpoints for clinical outcomes.